| abstract |
Disclosed is the use of an effective amount of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof in the manufacture of a medicament for treating a solid tumor in a patient, wherein the solid tumor is a neuroendocrine tumour of gut origin, of non-pancreatic origin, or of unknown primary origin; symptomatic endocrine producing neuroendocrine tumor; a non-functional neuroendocrine tumor; a locally unresectable, metastatic moderate, well differentiated, low (grade 1) or intermediate (grade 2) neuroendocrine tumour; non-small cell lung cancer; glioblastoma multiforme; hepatocellular carcinoma; breast cancer; colorectal cancer; salivary cancer; pancreatic cancer; adenocystic cancer; or adrenal cancer. Also disclosed are methods for treating or preventing a solid tumor, non- Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor of formula (I), (II), (III), or (IV) to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma. |